Cerus Corporation Культура компании

Mr. William M. Greenman, also known as Obi, has been the Chief Executive Officer and President of Cerus Corporation since April 2011. Mr. Greenman served as the Chief Business Officer of Cerus Corporation from April 1, 2010 to April 2011. He served as Senior Vice President of Business Development and Marketing at Cerus Corporation from August 2008 to April 2011 and also served as President of Cerus Europe from September 28, 2006 to August 2008. He was responsible for directing the European commercialization efforts for Cerus lead product, the INTERCEPT Blood System. He served as Vice President of Business Development of Cerus and has been a key member of Cerus management team. He has an extensive experience base at Cerus, having led business development, marketing and strategic planning activities for more than a decade. He led the restructuring of the Cerus's relationship with Baxter International, structured the relationships with both BioOne and MedImmune and was instrumental in establishing the Cerus European headquarters and staffing the European organization. Prior to joining Cerus in 1995 as director of business development, he served in various corporate development and marketing capacities for the Baxter Biotech Group, the biotech division of Baxter International from 1991 to 1995. He has been Director of Cerus Corporation since May 2004. He has been a Director at Aduro BioTech, Inc. since 2010. Mr. Greenman holds B.A.S. in Biological Sciences and Economics from Stanford University.

Dr. Richard J. Benjamin, M.D., MBChB, Ph.D. has been Chief Medical Officer of Cerus Corporation since July 13, 2015. Dr. Benjamin served as the chief medical officer at the American Red Cross since 2006. He oversaw the American Red Cross's donor and patient safety issues related to blood collection and transfusion. He served as a Member of Scientific Advisory Board of Immucor Inc. since November 2005. Dr. Benjamin served as a Member of Scientific Advisory Board of Point Therapeutics Inc. and served as its Director since July 7, 2004. He served as a Director of DARA BioSciences, Inc., until February 2008. Prior to joining the Red Cross, Dr. Benjamin served as a medical director at the Adult Transfusion Service at the Joint Program in Transfusion Medicine at Harvard University. Dr. Benjamin is well-versed in the INTERCEPT technology and previously served as an investigator in U.S Phase III studies for INTERCEPT platelets, plasma and red blood cells. Dr. Benjamin was a sub-investigator on Cerus??? Investigational Device Exemption (IDE) study for treatment of convalescent plasma collected from Ebola disease survivors for passive immune therapy within the United States. He is a board member and regional director for North America for the International Society of Blood Transfusion, as well as an active member of the AABB. He is an adjunct associate professor of pathology at Georgetown University in Washington, DC. He serves as an Assistant Professor of Pathology at Harvard Medical School and is a member of the Joint Program in Transfusion Medicine. His research is focused clinically on technologies to improve the safety and efficacy of transfusion. He serves as on the U.S Department of Health and Human Service's Advisory Committee on Blood Safety and Availability. He received his PhD in immunology from Cambridge University in England. Dr. Benjamin's medical degree is from the University of Cape Town, South Africa. He undertook completed his post-doctoral studies on the molecular mechanisms of antigen presentation at Stanford University, before initiating Hematopathology and Transfusion Medicine training at the Brigham and Womens Hospital.

Mr. Vivek K. Jayaraman has been the Chief Commercial Officer of Cerus Corporation since August 29, 2016. Mr. Jayaraman served as Vice President of Global Sales and Marketing at TriVascular Technologies, Inc. from October 2009 to August 2016. He served as Vice President of Commercial Operations at TriVascular Technologies, Inc. and led its Global Marketing, Sales and Business Development. He joined TriVascular from Medtronic, where he spent 8 years in roles of increasing leadership responsibility. Mr. Jayaraman served as the Vice President of Global Marketing for Medtronic's EVAR franchise and helped lead them to worldwide market share leadership. In previous roles, he managed the global P&L for Medtronic's Peripheral Vascular franchise, worked as a Policy Fellow in Medtronic's Government Affairs Office in Washington, D.C., and served as an expatriate in Hong Kong, SAR and Tokyo, Japan leading the gastroenterology and urology franchise. He joined Medtronic in business development supporting the Neurological and Diabetes sector. He worked at the Johnson & Johnson Development Corporation. He began his career as a consultant with The Wilkerson Group, a healthcare focused management consultancy. Mr. Jayaraman holds an MBA in Healthcare Management from The Wharton School at The University of Pennsylvania and dual bachelor's degrees in Biology and History from the University of Michigan.

Mr. Kevin D. Green has been the Chief Financial Officer of Cerus Corporation since February 28, 2013 and Vice President of Finance since May 2009. From January 2006 to February 2013, Mr. Green served in several roles at Cerus Corporation including Chief Accounting Officer since March 2009, Controller from January 2006 to May 2009, Chief Administrative Officer until March 2009 and also served as Senior Director of Finance and Principal Financial Officer. From 2000 to 2006, he held various financial management positions with Macromedia, Inc., a software company acquired by Adobe Systems in 2005, including Director of Finance and Assistant Controller. Prior to joining Macromedia, he was a Member of PricewaterhouseCoopers LLP in the Assurance and Business Advisory Services division. Mr. Green is a certified public accountant.

Dr. Laurence M. Corash, M.D. is a Co-Founder of Cerus Corporation and has been its Chief Scientific Officer since 2009 and serves as its Senior Vice President. Dr. Corash served as Senior Vice President of Cerus Corporation from March 2008 to July 13, 2015 and served as its Chief Medical Officer from 1994 to July 13, 2015. Dr. Corash served as Vice President of Cerus Corporation since July 1996, Director of Medical Affairs since July 1994 and Consultant from 1991 to July 1994. From February 1990 to July 1994, he served as a Consultant to the FDA Advisory Panel for Hematology Devices. He has been a Director at Cerus Corporation since December 2002. Dr. Corash has been a Professor of Laboratory Medicine at the University of California, San Francisco since July 1985 and was Chief of the Hematology Laboratory for the Medical Center of the University of California, San Francisco from January 1982 to 1997. He serves on the U.S. Health and Human Services' Advisory Committee on Blood Safety and Availability.

Ms. Chrystal N. Menard has been the Chief Legal Officer and General Counsel of Cerus Corporation since December 3, 2012. Ms. Menard was a Partner at Cooley LLP, where she practiced corporate and securities law from 2000 to 2011. She served as Senior Corporate Counsel at Zynga, Inc., where she had been since August 2011. Ms. Menard received her Juris Doctorate from the University of Chicago and her Bachelor of Science in finance and accounting from the University of Colorado, Boulder.

Ms. Suzanne Margerum serves as Vice President of Manufacturing and Operations at Cerus Corporation. Previously, Ms. Margerum served as Vice President of Manufacturing at Cerus Corporation since 2005. Since joining Cerus in 2001, she served as Vice President of Development; Director of Development; and Project Leader. Her previous experience includes 13 years at The Clorox Company in technical management (product development and manufacturing) for both U.S. and international business units. Ms. Margerum holds Bachelors and Master's degrees in Chemical Engineering.

Ms. Carol M. Moore has been Senior Vice President of Regulatory Affairs, Quality and Clinical of Cerus Corporation since 2013. Ms. Moore served as Vice President of Regulatory Affairs and Quality of Cerus Corporation since March 31, 2008. Ms. Moore was responsible for implementing global strategies for registration and regulatory compliance and with maintaining ISO quality standards related to the INTERCEPT Blood System. Prior to joining Cerus, she served as Vice President of worldwide regulatory affairs of Bayer Corporation. In that position, she held primary responsibility for interactions with health authorities worldwide involving the registration and regulatory compliance of Bayer's biological and biotech products. She was involved at Bayer in health policy, strategic planning, product development and acquisition assessment for a growing product portfolio. From 1999 to 2001, Ms. Moore served as Vice President of quality assurance and regulatory affairs of Bayer. She began her career at Bayer in 1976. Her biological products include those derived from recombinant and monoclonal sources, a well as transgenic and plasma-derived.

Lily Lin serves as the VP Global Scientific Affairs for Cerus Corporation. Lily started at Cerus Corporation in December of . Lily is based in the San Francisco Bay Area.